Blood-pressure-lowering peptide (FCVLRP)
A small natural peptide that blocks ACE, the enzyme that raises blood pressure, helping to lower blood pressure; studied as a potential treatment, not yet an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
What if the active ingredient only becomes active after your gut breaks down the original compound?
If the tiny fragment RP is doing most of the blood-pressure-lowering work, researchers could skip stabilizing the whole peptide and focus on delivering RP directly, which could lead to smaller, cheaper, more effective doses. This matters for anyone developing food-based or low-cost treatments for hypertension.
Can a blood pressure treatment avoid the side effects that come from disabling a protective enzyme your heart needs?
If FCVLRP turns out to be selective, it could lower blood pressure without suppressing the body's own counter-regulatory system, which some conventional ACE inhibitors interfere with. For patients and formulators, that could mean a cleaner safety profile compared to existing drugs.
Is there a naturally derived peptide that works better than the ones already used in functional foods for blood pressure?
If animal studies confirm the potency suggested by lab tests, FCVLRP or its fragment could become a competitive ingredient in functional foods or supplements aimed at mild hypertension, potentially requiring smaller amounts than the peptides currently used in products like fermented milk drinks.
If a natural peptide degrades too quickly to work well as a medicine, can a minor chemical tweak fix that without killing the effect?
If this modification holds up in testing, it could turn a fragile natural compound into a stable drug candidate with a longer shelf life and better absorption, which is a critical step in moving any peptide from a research finding toward a real product for people managing high blood pressure.
Could a peptide from food hit the same two targets as a major heart failure drug, but at a fraction of the cost?
The approved drug Entresto works by blocking both ACE and neprilysin together, a combination shown to reduce deaths in heart failure. If FCVLRP turns out to share that dual action, it could open a path to a much cheaper, food-derived approach to mild hypertension or early heart failure, though this remains entirely unproven and would need extensive testing.
Could you replace the inert middle of a peptide with something more durable, keeping the active ends intact?
If the valine-leucine segment is confirmed to be structural rather than active, drug designers could replace it with a non-peptide linker that resists breakdown in the gut, a standard strategy for turning peptides into orally stable drugs. That would be useful for anyone trying to develop this compound into a lasting antihypertensive treatment.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.6362297534942627 | boltz-2 |
| ranking score | 0.8214689493179321 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | colabfold_nvidia |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-25 |
▸citationbibtex
@peptide{pep04956,
sequence = {FCVLRP},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {computed}
}